Bank of America Corp DE Increases Holdings in Pharvaris (NASDAQ:PHVS)

Bank of America Corp DE boosted its stake in Pharvaris (NASDAQ:PHVS - Free Report) by 205,286.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,808 shares of the company's stock after acquiring an additional 30,793 shares during the period. Bank of America Corp DE owned 0.06% of Pharvaris worth $591,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. FMR LLC lifted its stake in Pharvaris by 3.6% in the fourth quarter. FMR LLC now owns 5,395,370 shares of the company's stock valued at $103,429,000 after buying an additional 189,714 shares during the period. Rock Springs Capital Management LP lifted its stake in Pharvaris by 2.4% in the fourth quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company's stock valued at $14,859,000 after buying an additional 18,200 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Pharvaris by 36.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock worth $8,510,000 after purchasing an additional 118,408 shares during the period. Northern Trust Corp raised its position in shares of Pharvaris by 483.9% during the fourth quarter. Northern Trust Corp now owns 91,932 shares of the company's stock worth $1,762,000 after purchasing an additional 76,188 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Pharvaris by 3.7% during the fourth quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock worth $735,000 after purchasing an additional 1,356 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on PHVS shares. Wedbush reaffirmed an "outperform" rating and set a $27.00 target price on shares of Pharvaris in a research report on Thursday, June 5th. Guggenheim started coverage on Pharvaris in a research report on Wednesday. They set a "buy" rating and a $32.00 target price on the stock. Finally, Cantor Fitzgerald lowered their price target on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Pharvaris has an average rating of "Buy" and a consensus target price of $36.20.

Pharvaris Stock Up 1.1%

NASDAQ PHVS traded up $0.18 on Thursday, reaching $17.23. The company had a trading volume of 6,095 shares, compared to its average volume of 74,696. The stock has a market capitalization of $900.96 million, a P/E ratio of -6.15 and a beta of -2.86. The company's fifty day moving average is $15.83 and its 200 day moving average is $16.95. Pharvaris has a 52-week low of $11.51 and a 52-week high of $25.50.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.09). On average, research analysts expect that Pharvaris will post -2.71 EPS for the current year.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.